Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Daejeon
Clinical trial register · South Korea

Clinical Trials in Daejeon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca16 Janssen Research & Development, LLC15 Merck Sharp & Dohme LLC13 Chungnam National University Hospital12 AbbVie9
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Daejeon

217 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Intuitive Surgical
Observational
151
Goyang-si, Daejeon, Seoul, Ulsan
2027-01
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Bucheon-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon
2026-10-26
Not yet open
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840Ischemic Stroke, Transient Ischemic Attack
DrugZastaprazan
Asan Medical Center
Phase 3
984
Daejeon, Gwangju, Gyeonggi-do, Incheon, Jeju City, Jeonju, Seoul
2026-10-15
Not yet open
Chonnam National University Hospital
Not applicable
1,252
Bucheon-si, Changwon, Cheonan, Cheongju-si, Chuncheon, Daegu, Daejeon, Gwangju
2026-09-01
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seongbuk-Gu, Seoul
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Guri-si, Junggu, Seoul
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,500
Busan, Daegu, Daejeon, Incheon, Seoul, Suwon
2026-08-20
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Daegu, Daejeon, Seongnam, Seoul
2026-08-05
Recruiting
AstraZeneca
Phase 3
1,200
Busan, Changwon-si, Daegu, Daejeon, Guri-si, Incheon, Seoul
2026-07-06
Not yet open
Efficacy of Verciguat in TR and RV Failure
NCT07668739HFrEF, Tricuspid Regurgitation (TR)
DrugVericiguat
Daejeon St. Mary's hospital
Phase 4
100
Daejeon
2026-07-01
Recruiting
Seoul National University Hospital
Phase 4
1,292
Daejeon, Seoul
2026-06-22
Recruiting
Chungnam National University Hospital
Observational
300
Daejeon
2026-06-11
Recruiting
Pfizer
Phase 3
954
Daejeon, Anyang-si, Yangsan, Incheon, Seoul
2026-06-10
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Wŏnju, Busan, Daegu, Daejeon, Seoul
2026-06-08
Recruiting
Samsung Medical Center
Observational
396
Daegu, Daejeon, Seongnam-si, Yangsan, Incheon, Jeju City, Jeonju, Hwasun
2026-05-28
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Busan, Daejeon, Gangnam Gu, Seoul
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Busan, Daejeon, Gangnam Gu, Seoul
2026-05-22
Recruiting
Transition of Care in Pediatric Rare Endocrine Disorders
NCT07786142Endocrine Disorder, Rare Disorders
Seoul National University Hospital
Not applicable
150
Daegu, Daejeon, Gwangju, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2026-05-20
Recruiting
Chungnam National University
Not applicable
160
Daejeon
2026-05-13
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Wŏnju, Anyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Daegu, Daejeon
2026-05-11
Recruiting
Chungnam National University
Not applicable
288
Daejeon
2026-05-10
Recruiting
Safety and Effectiveness of Ultrasound-guided Pharmacopuncture for Spinal Diseases
NCT07543692Spinal Disease, Neck Pain, Low Back Pain, Radiculopathy
Jaseng Medical Foundation
Observational
600
Daejeon, Seoul, Bucheon-si, Yangsan
2026-04-29
Recruiting
The DECISION-CTO Extended 10 Y Follow-up
NCT06908499Coronary Artery Disease
Seung-Jung Park
Observational
840
Anyang, Bucheon-si, Busan, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2026-04-01
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Busan, Daegu, Daejeon, Gwangju, Gyeongsan-si, Pusan, Seoul, Wŏnju
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Daejeon, Dongjak Gu, Seoul, Busan
2026-03-24
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Seongnam-si, Daejeon, Gangwon-do, Gwangju, Gyeonggi-do, Seoul
2026-03-23
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Daegu, Seongnam-si, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seoul
2026-03-16
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
45
Seongnam-si, Hwasun, Busan, Daegu, Daejeon, Seoul
2026-02-12
Recruiting
Pharmacopuncture for Aromatase Inhibitor Induced Arthralgia (AIA)
NCT07789717Breast Cancer, Aromatase Inhibitor, Aromatase Inhibitor Induced Arthralgia
Ilsan Cha hospital
Not applicable
30
Daejeon, Goyang-si, Incheon
2026-01-05
Recruiting
Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics
NCT07481396Cardiac Arrest (CA), Cerebrospinal Fluid, Multiomics, Hypoxic-Ischemic Brain Injury
Chungnam National University Hospital
Observational
60
Daejeon
2025-12-01
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
75
Daegu, Daejeon, Seoul, Wŏnju
2025-11-26
Recruiting
Gachon University Gil Medical Center
Phase 4
64
Busan, Chungju, Daegu, Daejeon, Gwangju, Incheon, Seoul, Wŏnju
2025-11-24
By invitation
Novo Nordisk A/S
Observational
500
Goyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon
2025-11-10
Recruiting
AstraZeneca
Observational
130
Busan, Daejeon, Goyang-si, Guri-si, Incheon, Seongnam-si, Seoul, Suwon
2025-10-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Jeollanam-do, Yangsan, Busan, Daejeon, Seoul
2025-10-08
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Cheonan-si, Daejeon, Seoul
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Busan, Daegu, Daejeon, Dongdaemun-gu, Seongnam-si, Seoul, Suwon
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Busan, Daegu, Daejeon, Seoul, Suwon
2025-10-01
Recruiting
Sanofi
Phase 3
980
Ansan-si, Busan, Daegu, Daejeon, Gwangju, Seoul, Suwon
2025-10-01
Recruiting
Genentech, Inc.
Phase 2
224
Wŏnju, Busan, Daejeon, Gwangju, Seoul
2025-09-29
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Daejeon, Daegu, Busan-si, Pusan, Ulsan, Namdong, Hwasun, Seoul
2025-09-26
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Anyang-si, Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Gwangju
2025-09-22
Recruiting
Chungnam National University Hospital
Not applicable
22
Daejeon
2025-09-11
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Busan, Daejeon, Goyang, Seongnam, Seoul, Suwon
2025-09-08
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Daejeon, Goyang-si, Hwasungun, Seoul
2025-09-02
Recruiting
Jung-min Ahn
Phase 4
5,000
Anyang, Bucheon-si, Busan, Changwon, Cheonju, Chuncheon, Daegu, Daejeon
2025-07-24
Recruiting
Pusan National University Yangsan Hospital
Phase 2
186
Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2025-07-23
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Ansan-si, Bucheon-si, Busan, Daejeon, Daejoen, Gwangju, Incheon, Seongnam
2025-07-22
Active, closed
Multiomics Profiling of CSF in Cardiac Arrest Survivors
NCT07090577Cardiac Arrest (CA), Hypoxic-Ischemic Brain Injury, Post-Resuscitation Syndrome
Chungnam National University Hospital
Observational
15
Daejeon
2025-07-22
Recruiting
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT07002164Myocardial Infarction (MI), Heart Failure
Chonnam National University Hospital
Not applicable
780
Changwon, Daegu, Daejeon, Gwangju, Jeonju, Jinju, Pusan, Seongnam
2025-07-15
Recruiting
Asan Medical Center
Phase 4
2,340
Seoul, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon
2025-07-10
Recruiting
JW Pharmaceutical
Observational
10,000
Daejeon
2025-06-25
Active, closed
AbbVie
Phase 3
573
Busan, Daegu, Daejeon, Seongnam-si, Suwon, Gwangju, Seoul
2025-06-17
Recruiting
Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy
NCT06984952Enhanced Recovery After Surgery, Gastrectomy for Gastric Cancer
Seoul National University Hospital
Not applicable
308
Busan, Daegu, Daejeon, Goyang, Seongnam, Seoul, Suwon
2025-06-13
Active, closed
Eisai Korea Inc.
Phase 4
94
Busan, Daegu, Daejeon, Gyeonggi-do, Gyeongnam, Jungnam, Seoul
2025-06-11
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Daejeon, Goyang-si, Gyeonggi-do, Seoul
2025-06-04
Recruiting
AstraZeneca
Phase 3
15,100
Bucheon-si, Busan, Changwon-si, Daegu, Daejeon, Goyang-si, Gwangju, Gwangmyeong
2025-06-04
Not yet open
Next Biomedical Co., Ltd.
Not applicable
60
Cheongju-si, Daejeon, Gwangju, Sejong, Seoul, Yangsan
2025-06
Active, closed
AstraZeneca
Phase 3
3,103
Anyang-si, Bucheon-si, Busan, Changwon-si, Cheonan-si, Daegu, Daejeon, Gangwon-do
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Busan, Daegu, Daejeon, Seoul, Suwon, Wŏnju
2025-05-27
Recruiting
Jaseng Medical Foundation
Not applicable
40
Daejeon
2025-05-22
Recruiting
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
NCT06902545Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugZolbetuximab
Astellas Pharma Korea, Inc.
Observational
377
Goyang-si, Suwon, Yangsan, Hwasun Gun, Daejeon, Seoul
2025-04-03
Recruiting
Hoffmann-La Roche
Phase 3
600
Busan, Daegu, Daejeon, Gangwon-do, Guri-si, Seoul
2025-03-17
Active, closed
Amgen
Phase 3
3,853
Ansan-si, Gyeonggi-do, Anyang-si, Gyeonggi-do, Bucheon, Gyeonggi-do, Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon
2025-03-12
Recruiting
Chungnam National University Hospital
Not applicable
150
Jeonju, Daejeon
2025-03-06
Recruiting
Dianthus Therapeutics
Phase 3
256
Daegu, Daejeon, Seoul, Uijeongbu-si, Yangsan
2025-02-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Goyang-si, Busan, Daejeon, Seoul
2025-01-27
By invitation
Chungnam National University Hospital
Observational
200
Daejeon
2025-01-24
Recruiting
BioNTech SE
Phase 2/3
1,580
Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon
2025-01-07
Recruiting
Takeda
Phase 3
396
Busan, Daegu, Daejeon, Seoul, Suwon
2025-01-02
Recruiting
Duk-Woo Park, MD
Phase 4
1,040
Bucheon-si, Changwon, Daegu, Daejeon, Gangneung, Gwangju, Ilsan, Incheon
2024-12-18
Recruiting
Yonsei University
Phase 2
40
Daegu, Daejeon, Hwasun, Jeju City, Pusan, Seoul
2024-12-11
Active, closed
Sanofi
Phase 2
260
Haeundae-Gu, Daegu, Daejeon, Wŏnju
2024-12-10
Active, closed
Amgen
Phase 3
707
Daejeon, Goyang-si, Gyeonggi-do, Seongnam-si, Gyeonggi-do, Seoul
2024-12-09
Active, closed
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
NCT06712615Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
DrugPG-102
ProGen. Co., Ltd.
Phase 2
144
Bucheon-si, Daegu, Daejeon, Seongnam, Seoul
2024-12-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Pusan Kwangyokshi, Daejeon, Seoul
2024-11-21
By invitation
Novo Nordisk A/S
Observational
840
Goyang-si, Busan, Chungcheongnam-do, Daejeon, Gyeonggi-do, Seoul, Yangsan
2024-11-19
By invitation
Pusan National University Hospital
Not applicable
200
Busan, Daegu, Daejeon
2024-11-01
Recruiting
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
NCT06257394Acute Lymphoblastic Leukemia, Pediatric
Hyoung Jin Kang
Phase 2
74
Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
2024-10-20
Recruiting
Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
NCT06649240Ischemic Stroke, Small Vessel Cerebrovascular Disease, Cholesterol, LDL, Secondary Prevention
DrugsBiweekly·Ezetimibe
Seoul National University Hospital
Not applicable
4,016
Ansan, Anyang, Busan, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon
2024-10-04
Recruiting
AbbVie
Observational
3,000
Busan, Daejeon, Gangwon-do, Gwangju, Ansan-si, Goyang, Goyang-si, Hwaseong
2024-09-24
Recruiting
AbbVie
Phase 2
590
Busan, Daejeon, Seoul, Daegu
2024-09-04
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Anyang, Cheonan, Daegu, Daejeon, Gangwon-do, Goyang-si, Seongnam-si, Seoul
2024-08-30
Recruiting
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
NCT06519162Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
Chungnam National University Hospital
Observational
3,000
Daejeon
2024-07-08
Active, closed
Jaseng Medical Foundation
Not applicable
250
Bucheon-si, Daejeon, Haeundae, Seoul, Yangsan
2024-07-07
Recruiting
AstraZeneca
Phase 3
240
Daejeon, Seoul
2024-06-20
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Bucheon-si, Busan, Cheongju-si, Daejeon, Deagu, Gwangju, Incheon, Seongnam
2024-06-17
Recruiting
Real-World Treatment Study of Koselugo (Selumetinib)
NCT06360406Neurofibromatosis 1, Neurofibroma, Plexiform
AstraZeneca
Observational
200
Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju
2024-06-15
Recruiting
Duk-Woo Park, MD
Not applicable
1,500
Bucheon-si, Daegu, Daejeon, Gangneung, Gwangju, Ilsan, Incheon, Pusan
2024-06-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Bupyeong-gu, Yangsan, Busan, Deagu, Daejeon, Seoul
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Wŏnju, Ansan-si, Suwon, Busan, Haeundae-gu, Dongjak-gu, Daegu, Daejeon
2024-06-05
Recruiting
CMG Pharmaceutical Co. Ltd
Phase 3
240
Anyang, Buchon, Busan, Cheonan, Daegu, Daejeon, Goyang-si, Guri-si
2024-04-19
Recruiting
AstraZeneca
Phase 3
3,850
Anyang-si, Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gwangmyeong
2024-04-12
Recruiting
Ho Joon Im
Phase 2
90
Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
2024-04-04
Active, closed
AstraZeneca
Phase 3
2,554
Ansan-si, Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Gwangju, Seoul
2024-03-29
Active, closed
Gilead Sciences
Phase 2
228
Busan, Daegu, Daejeon, Guri-si, Jongno-Gu, Nam-Gu, Seongdong-gu, Seoul
2024-03-27
Active, closed
AbbVie
Phase 2
156
Busan, Daejeon, Seoul
2024-03-23
Recruiting
Hee Young Ju
Phase 2
116
Seoul, Yangsan, Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Suwon
2024-03-05
Active, closed
Eli Lilly and Company
Phase 3
17,300
Bucheon-si, Daegu, Daejeon, Dongjak-gu, Gwangju, Namdong-gu, Seongnam, Seoul
2024-03-05
Active, closed
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
NCT05995600Antiphospholipid Syndrome, Ischemic Stroke, Transient Ischemic Attack, Cerebrovascular Disease
DrugWarfarin
Seoul National University Hospital
Phase 4
200
Anyang, Busan, Cheongju-si, Chuncheon, Daegu, Daejeon, Guri-si, Gwangju
2024-02-20
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
Daejeon, Gyeonggi-do, Seoul
2024-02-01
Active, closed
BicycleTx Limited
Phase 2
375
Daejeon, Goyang, Seoul
2024-01-24
Recruiting
Colorado Prevention Center
Phase 3
5,200
Gwangju, Wŏnju, Seoul, Bucheon-si, Incheon, Daejeon, Cheongju-si, Busan
2024-01-17
Active, closed
AbbVie
Phase 3
614
Daejeon, Bucheon-si, Suwon, Seoul
2023-12-19
Active, closed
Cellid Co., Ltd.
Phase 3
4,000
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seoul
2023-11-27
Active, closed
AstraZeneca
Phase 3
1,898
Daejeon, Seongnam-si, Seoul, Suwon
2023-11-21
Active, closed
AbbVie
Phase 3
289
Busan, Daejeon, Suwon, Seoul, Daegu
2023-11-15
Active, closed
Bristol-Myers Squibb
Phase 2
227
Pusan, Daejeon, Gwangju, Seongnam, Junggu, Seoul, Daegu
2023-11-07
Recruiting
Astellas Pharma Korea, Inc.
Observational
202
Goyang-si, Suwon, Jeollanam-do, Jeonju, Busan, Daegu, Daejeon, Incheon
2023-11-01
By invitation
Chungnam National University Hospital
Observational
40
Daejeon
2023-11-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Wŏnju, Suwon, Busan, Haeundae-gu, Dongjak-gu, Daegu, Daejeon, Seoul
2023-10-25
Recruiting
Hoffmann-La Roche
Phase 3
182
Daejeon, Seoul
2023-10-22
Active, closed
Yuhan Corporation
Phase 4
198
Wŏnju, Seoul, Busan, Daejeon, Gwangju, Gyeonggi-do, Incheon
2023-10-18
Recruiting
AbbVie
Phase 3
1,500
Busan, Daegu, Daejeon, Seongnam-si, Incheon, Jeonju, Seoul
2023-10-11
Recruiting
Samsung Medical Center
Not applicable
2,000
Bucheon-si, Chuncheon, Chungju, Daegu, Daejeon, Gwangju, Gwangmyeong, Ilsan
2023-10-02
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Busan, Daegu, Daejeon, Goyang-si, Jeollanam-do, Seoul
2023-09-18
Recruiting
Ipsen
Phase 3
276
Bucheon-si, Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Junggu
2023-08-31
Recruiting
Chungnam National University Hospital
Not applicable
40
Daejeon
2023-08-28
Recruiting
Jaseng Medical Foundation
Not applicable
200
Seoul, Bucheon-si, Busan, Daejeon
2023-08-09
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Seongnam-si, Suwon, Incheon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-08-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Daegu, Daejeon, Seoul
2023-07-19
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Dongan-Gu, Anyang-Si, Guri-si, Uijeongbu-si, Jongno-gu, Seodaemun-gu, Seongbuk-Gu, Cheonan, Daejeon
2023-07-06
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Incheon, Suwon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-06-30
Recruiting
Novartis Pharmaceuticals
Observational
44
Daegu, Suwon, Incheon, Seoul, Busan, Daejeon, Jeollanam
2023-06-12
Recruiting
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
NCT06088121Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Advanced Technology & Communications
Not applicable
180
Incheon, Gwangmyeong, Jeonju, Gwangju, Daegu, Gyeonggi-do, Daejeon, Seoul
2023-05-15
Recruiting
GC Biopharma Corp
Phase 3
105
Goyang-si, Suwon, Seoul, Busan, Daejeon
2023-04-13
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Anyang-si, Busan, Cheonan-si, Cheongju-si, Chuncheon, Daegu, Daejeon, Goyang-si
2023-04-11
By invitation
Seung-Whan Lee, M.D., Ph.D.
Phase 4
4,000
Bucheon-si, Changwon, Cheonju, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2023-03-14
Active, closed
AstraZeneca
Phase 2
188
Busan, Cheongju-si, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2023-03-06
Recruiting
Eli Lilly and Company
Phase 3
595
Busan, Cheonan-si, Daejeon, Incheon, Jeonju, Junggu, Seongnam-si, Seoul
2023-02-27
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Anyang-si, Busan, Daegu, Daejeon, Goyang-si, Gwangju, Incheon, Jeju Special
2023-02-15
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Daejeon, Seoul
2023-02-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Hwasun, Pusan, Daejeon, Seoul
2023-02-06
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Wŏnju, Seongnam-si, Suwon, Daegu, Ansan-si, Busan, Daejeon, Incheon
2023-01-16
Active, closed
Sanofi
Phase 2
68
Haeundae-gu, Daegu, Daejeon, Wŏnju
2023-01-12
Active, closed
Exelixis
Phase 3
317
Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
2023-01-01
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Anyang-si, Busan, Daegu, Daejeon, Goyang-si, Gwangju, Gyeonggi-do, Seongnam-si
2022-12-27
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Bucheon-si, Seongnam-si, Yangsan, Daegu, Daejeon, Incheon, Seongnam-si, Gyeonggi-do, Seoul
2022-11-01
Recruiting
Asan Medical Center
Phase 4
3,944
Bucheon-si, Busan, Changwon, Chuncheon, Chungju, Daegu, Daejeon, Gangneung
2022-10-21
By invitation
Comparison Study Between Suction Aspiration and Combination Technique in Acute Cerebral Infarction
NCT06254755Acute Cerebral Ischemia Requiring for Mechanical Thrombectomy
Inje University Haeundae Paik Hospital
Not applicable
1,132
Goyang-si, Seongnam-si, Changwon, Bucheon-si, Daegu, Daejeon, Incheon, Pohang
2022-10-01
Active, closed
Seoul National University Bundang Hospital
Observational
1,000
Bucheon-si, Chungju, Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju
2022-09-28
Active, closed
Biogen
Phase 2/3
450
Ansan-si, Suwon, Daejeon, Gwangju, Seoul
2022-09-13
Active, closed
Scrub Typhus Infection Induced Cardiovascular Disease
NCT03274869Scrub Typhus, Cardiovascular Complication
Eulji University Hospital
Observational
100
Chungju, Daejeon
2022-09-01
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Daejeon, Gyeonggi-do, Seongnam-si, Seoul
2022-08-17
Active, closed
Gilead Sciences
Phase 2/3
689
Daegu, Daejeon, Seoul
2022-08-16
Active, closed
Bausch Health Americas, Inc.
Phase 3
466
Busan, Daegu, Daejeon, Gangwon-do, Goyang-si, Gyeonggi-do, Gyeongsang, Seongnam-si
2022-08-03
Recruiting
Novartis Pharmaceuticals
Observational
900
Cheonan Si, Daegu, Goyang-si, Suwon, Gyeonggi-do, Seoul, Busan, Daejeon
2022-06-29
Recruiting
Actelion
Phase 3
280
Daejeon, Incheon, Seoul
2022-05-04
Active, closed
Hoffmann-La Roche
Phase 3
208
Busan, Daejeon, Seoul
2022-04-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Hwasun, Deagu, Daejeon, Seoul
2022-03-24
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Busan, Daegu, Daejeon, Dongdaemun-gu, Goyang-si, Gwangju, Gyeonggi-do, Seoul
2022-01-19
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
Busan, Daegu, Daejeon, Dongan, Goyang-si, Jeonju, Seongnam, Seoul
2022-01-15
Active, closed
Amgen
Phase 3
303
Busan, Daejeon, Hwasun, Seoul
2021-11-02
Active, closed
AstraZeneca
Phase 3
148
Daejeon, Goyang-si, Incheon, Seoul
2021-10-28
Recruiting
Chungnam National University Hospital
Observational
150
Daejeon
2021-08-18
Recruiting
Regulatory Post-Marketing Surveillance Study for Brolucizumab
NCT04985487Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals
Observational
3,000
Daegu, Goyang-si, Guri-si, Suwon, Iksan Si, Daejeon, Busan, Gwangju
2021-08-18
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gangseo-gu, Goyang-si, Incheon
2021-08-14
Active, closed
HUYABIO International, LLC.
Phase 3
450
Goyang-si, Seongnam-si, Seoul, Hwasun, Daejeon
2021-08-12
Recruiting
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
DrugsLenvatinib·Keytruda·Pembrolizumab
GI Innovation, Inc.
Phase 1/2
317
Seoul, Daejeon, Suwon
2021-08-02
Recruiting
Chungnam National University Hospital
Phase 2/3
308
Daejeon
2021-07-06
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Anyang-si, Busan, Daejeon, Goyang-si, Hwasun-gun, Seongnam-si, Seoul, Suwon
2021-06-24
Active, closed
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634Head and Neck Squamous Cell Carcinoma, Oral Mucositis
DrugCCRT
MitoImmune Therapeutics
Phase 2
60
Suwon, Jeonju, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seoul
2021-06-21
Active, closed
Incyte Corporation
Phase 3
654
Busan, Daegu, Daejeon, Incheon, Jeonju, Seoul
2021-04-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Goyang-si, Daejeon, Seoul
2021-04-14
Active, closed
ALX Oncology Inc.
Phase 2
189
Cheongju-si, Daegu, Daejeon, Gyeonggi-do, Incheon, Seongnam, Seoul, Suwon
2021-04-02
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Anyang, Daejeon, Gyeonggi-do, Jeju City, Seongnam-si, Seoul
2020-12-11
Active, closed
Kyungpook National University Hospital
Phase 2
364
Daegu, Daejeon, Gwangju, Incheon, Jeonju, Seoul
2020-10-23
Recruiting
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
NCT04499859Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
DrugsEzetimibe·Rosuvastatin
Kiyuk Chang, MD,PhD
Phase 4
3,548
Bucheon-si, Suwon, Uijeongbu-si, Daejeon, Incheon, Seoul
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Seongnam-si, Seoul, Suwon
2020-09-23
Recruiting
Duk-Woo Park, MD
Observational
2,000
Chuncheon, Daegu, Daejeon, Gangneung, Kwangju, Pusan, Seoul, Suncheon
2020-09-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Gyeonggi-do, Seongnam-si, Daejeon, Seoul
2020-05-19
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Daejeon, Goyang-si, Hwasun, Seongnam-si, Seoul
2020-03-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Gyeonggi-do, Daejeon, Seoul
2020-02-27
Recruiting
Asan Medical Center
Observational
3,000
Bucheon-si, Busan, Changwon, Chuncheon, Daegu, Daejeon, Gangneung, Jeonju
2020-02-20
Active, closed
Eli Lilly and Company
Phase 3
261
Goyang-si, Seongnam-si, Incheon, Seoul, Jinju, Dongjak-gu, Daejeon
2020-02-17
Active, closed
Role of FFR in ACS Patients: Pressure ACS Registry
NCT05896501Acute Coronary Syndrome
The Catholic University of Korea
Observational
500
Suwon, Uijeongbu-si, Daejeon, Incheon, Seoul
2020-01-01
Active, closed
EHL Bio Co., Ltd.
Phase 2
118
Daejeon, Ansan, Seoul
2019-12-11
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Daejeon, Jeju City, Jeju-do, Seoul
2019-11-13
Active, closed
Clinical Impact of Orsiro™ Stent in Patient With Chronic Kidney Disease
NCT06475625Chronic Kidney Diseases, Coronary Artery Disease
The Catholic University of Korea
Phase 4
3,113
Daejeon
2019-10-22
Active, closed
Novo Nordisk A/S
Phase 3
134
Daejeon, Seoul
2019-10-21
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Daegu, Daejeon, Seoul
2019-08-15
Active, closed
Biogen
Observational
74
Busan, Changwon, Cheongju-si, Daegu, Daejeon, Gwangju, Jeonju, Seoul
2019-07-02
Recruiting
Transpacific TAVR Registry
NCT03826264Heart Valve Diseases, Aortic Valve Insufficiency
Duk-Woo Park, MD
Observational
10,000
Bucheon-si, Daejeon, Seoul
2019-06-15
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Cheongju-si, Daejeon, Goyang, Incheon, Seoul
2019-03-22
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Seongnam-si, Seoul
2019-01-25
Recruiting
Seung-Jung Park
Observational
500
Bucheon-si, Daegu, Daejeon, Gwangju, Pusan, Seongnam, Seoul
2018-09-04
Active, closed
AbbVie
Phase 3
1,242
Busan, Daejeon, Guri-si, Seongnam, Suwon, Seoul, Daegu
2018-08-28
Active, closed
Eli Lilly and Company
Phase 3
1,058
Busan, Daejeon, Gyeongsan-si, Haeundae-gu, Seoul, Wŏnju
2018-07-18
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
Seongnam, Seoul, Daejeon
2018-04-17
Active, closed
Seung-Jung Park
Not applicable
2,008
Daegu, Daejeon, Gwangju, Pusan, Seoul
2018-04-12
Active, closed
AbbVie
Phase 3
1,336
Busan, Daegu, Daejeon, Guri-si, Seongnam-si, Suwon, Seoul
2018-04-09
Active, closed
Janssen Research & Development, LLC
Phase 1/2
125
Daejeon, Gwangju, Gyeonggi-do, Seoul, Yangsan
2018-04-05
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Busan, Daejeon, Goyang-si, Gwangju, Gyeonggi-do, Incheon, Seoul, Wŏnju
2018-03-23
Recruiting
Eulji University Hospital
Observational
1,000
Chungju, Daejeon, Seoul
2018-01-30
Recruiting
Seung-Whan Lee, M.D., Ph.D.
Observational
4,000
Anyang, Bucheon-si, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon, Gangneung
2018-01-11
Active, closed
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Wŏnju, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Busan, Daegu, Daejeon
2017-12-18
Active, closed
ViiV Healthcare
Phase 3
1,049
Daegu, Daejeon, Pusan, Seoul
2017-10-27
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
DrugsSavolitinib·Sunitinib
AstraZeneca
Phase 3
60
Daejeon, Goyang-si, Hwasun-gun, Incheon, Seoul
2017-07-25
Active, closed
Kyung Hee University Hospital at Gangdong
Phase 3
358
Busan, Cheonan, Chuncheon, Daegu, Daejeon, Hwasun, Iksan, Seoul
2016-12-07
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Daejeon, Gwangju, Jeonju, Seoul, Suwon, Ulsan
2016-12
Recruiting
Kee-joon Choi
Phase 4
140
Bucheon-si, Busan, Cheonan, Daegu, Daejeon, Gangneung, Gwangju, Iksan
2016-11-29
Active, closed
ViiV Healthcare
Phase 3
618
Daegu, Daejeon, Pusan, Seoul
2016-10-28
Active, closed
IRIS-Synergy Cohort in the IRIS-DES Registry
NCT02720419Coronary Artery Disease
Jung-min Ahn
Observational
3,000
Bucheon-si, Busan, Cheonan, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2016-08
Recruiting
Seung-Jung Park
Observational
4,000
Seoul, Busan, Cheonan, Daegu, Daejeon, Ilsan, Incheon, Jeju City
2016-07
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Daegu, Daejeon, Goyang-si, Jeollanam-do, Seongnam-si, Seoul
2015-11-27
Active, closed
IRIS-Onyx Cohort in the IRIS-DES Registry
NCT02593994Coronary Artery Disease, Arterial Occlusive Diseases, Cardiovascular Diseases, Percutaneous Transluminal Angioplasty
Seung-Jung Park
Observational
4,500
Seoul, Anyang, Bucheon-si, Cheonan, Chuncheon, Daegu, Daejeon, Gangneung
2015-10
Active, closed
AstraZeneca
Phase 3
1,118
Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Incheon, Jinju
2015-07-21
Active, closed
Janssen Research & Development, LLC
Phase 2
239
Daejeon, Goyang-si, Incheon, Seoul
2015-04-22
Recruiting
Drug-Eluting Balloon Registry in Routine Clinical Practice
NCT02038660Coronary Artery Disease, Angioplasty, Balloon
Seung-Jung Park
Observational
1,500
Bucheon-si, Daegu, Daejeon, Gwangju, Pusan, Seoul, Ulsan
2014-01
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Yangsan, Busan, Changwon, Cheongju-si, Daegu, Daejeon, Gangneung, Gwangju
2012-01
Active, closed
Biliary Complication Rates in Living Donor Liver Transplantation: a Retrospective Comparative Study of Stent Versus Non-Stent Groups
NCT06767553Liver Failure, Living Donor Liver Transplantation, Biliary Complications, Biliary Stents
Chungnam National University Hospital
Observational
160
Daejeon
2011-11-01
Recruiting
Seung-Jung Park
Observational
20,000
Anyang, Bucheon-si, Cheongju-si, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2011-06
Recruiting
Observational Study for Left Main Disease Treatment
NCT01341327Coronary Artery Disease
Seung-Jung Park
Observational
10,000
Anyang, Bucheon-si, Busan, Cheonan, Cheongju-si, Daegu, Daejeon, Gangneung
2007-07
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Yangsan, Seoul, Daejeon
2004-09-15
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Suwon, Yangsan, Jeju City, Seoul, Busan, Daejeon
2001-07-31
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Yangsan, Seoul, Daejeon
1991-04-01
Recruiting
Medtronic
Observational
20,000
Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Jeonju, Seongnam-si
1983-01
Rows per page Showing 1–217 of 217
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/daejeon

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 217 of those studies with a site in Daejeon.

How many clinical trials are recruiting in Daejeon?

112 of the 217 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 90 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Daejeon), 217 studies
PhaseStudiesRecruitingShare
Phase 3953943.8%
Observational463321.2%
Phase 2271112.4%
Not applicable21159.7%
Phase 41596.9%
Phase 2/31034.6%
Phase 1/2210.9%
Phase 1110.5%

Most active sponsors

Lead sponsors with the most studies (Daejeon)
Lead sponsorStudiesRecruiting
AstraZeneca169
Janssen Research & Development, LLC156
Merck Sharp & Dohme LLC134
Chungnam National University Hospital128
AbbVie93
Novo Nordisk A/S81
Seung-Jung Park86
Hoffmann-La Roche64
Novartis Pharmaceuticals64
Eli Lilly and Company52
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.